• Updated Competitor Analysis G-CSF and GM-CSF

R&D Pipeline:

• Ipsen (France)

• 2005 sales of branded G-CSF products of US$ 4 bln;
• European biogeneric G-CSF in clinical development;
• Next generation longer-acting G-CSF still in preclinical development;
• Numerous off-patent manufacturers of G-CSF in South America and Asia ;
• Pegylated G-CSF in non-regulated markets already in clinical development;
• Existing GM-CSF market rather limited;
• Market expansion of GM-CSF expected for new indication Crohn's disease


More Details inside R&D Pipeline News
Get you annual subscription and receive this issue for free!

• ImaRx acquired all thrombolytic projects from Abbott;
• Innovative combinations of thrombolytic with ultrasound;
• New uses of thrombolytics for cancer and visual disorders;
• Strong interest in thrombolytics which directly lyse fibrin;
• Plasmin and microplasmin as novel thrombolytics
• No biogeneric thrombolytics in Europe , but plenty in emerging markets;
• Biogenerics include rec streptokinase, t-PA, tenecteplase and reteplase.

More Details inside R&D Pipeline News
Get you annual subscription and receive this issue for free!